FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice

被引：5
|
作者：
Angerilli, Valentina [1 ]
Fornaro, Lorenzo [2 ]
Pepe, Francesco [3 ]
Rossi, Silvia Maria [4 ,5 ]
Perrone, Giuseppe [4 ,5 ]
Malapelle, Umberto [3 ]
Fassan, Matteo [1 ,6 ]
机构：
[1] Univ Padua, Dept Med DIMED, Surg Pathol Unit, Padua, PD, Italy
[2] Azienda Osped Univ Pisana, Med Oncol, Pisa, PI, Italy
[3] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy
[4] Univ Campus Bio Med Roma, Dept Med & Surg, Res Unit Anat Pathol, Rome, Italy
[5] Fondazione Policlin Univ Campus Bio Med, Anat Pathol Operat Res Unit, Rome, Italy
[6] IOV IRCCS, Veneto Inst Oncol, Padua, Italy
来源：
PATHOLOGICA | 2023年 / 115卷 / 02期
关键词：
cholangiocarcinoma; precision medicine; FGFR2; biomarkers; OPEN-LABEL; METASTATIC CHOLANGIOCARCINOMA; FORMALIN FIXATION; SINGLE-ARM; RNA; MULTICENTER; FUSIONS; CHEMOTHERAPY; BGJ398; TISSUE;
D O I：
10.32074/1591-951X-859
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms burdened by a dismal prognosis. Several studies have investigated the genomic profile of CCA and identi!ed numerous druggable genetic alterations, including FGFR2 fusions/rearrangements. Approximately 5-7% of CCAs and 10-20% of intrahepatic iCCAs harbor FGFR2 fusions. With the recent advent of FGFR-targeting therapies into clinical practice, a standardization of molecular testing for FGFR2 alterations in CCA will be necessary. In this review, we describe the technical aspects and challenges related to FGFR2 testing in routine practice, focusing on the comparison between Next-Generation Sequencing (NGS) and FISH assays, the best timing to perform the test, and on the role of liquid biopsy.
引用
收藏
页码：71 / 82
页数：12
相关论文
共 50 条
  • [21] FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma
    Huang, X-W.
    Shi, G-M.
    Zhang, T.
    Bao, L-Q.
    Wen, T-F.
    Zhang, B.
    Peng, T.
    Zhao, H.
    Kuang, M.
    Wang, W-L.
    Ran, J-H.
    Liu, Y-B.
    Gong, W.
    Mou, H-B.
    Luo, Y.
    Wang, Y.
    Sun, H.
    Fan, J.
    Liu, L-X.
    Dai, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S379 - S379
  • [22] Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling
    Silverman, Ian M.
    Li, Meijuan
    Murugesan, Karthikeyan
    Krook, Melanie A.
    Javle, Milind M.
    Kelley, Robin K.
    Borad, Mitesh J.
    Roychowdhury, Sameek
    Meng, Wei
    Yilmazel, Bahar
    Milbury, Coren
    Shewale, Shantanu
    Feliz, Luis
    Burn, Timothy C.
    Albacker, Lee A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (04): : 351 - 364
  • [23] FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma
    Cao, Zi
    Yang, Yichen
    Liu, Shasha
    Sun, Lin
    Liu, Yanxue
    Luo, Ye
    Wang, Jian
    Sun, Yan
    JOURNAL OF GASTROENTEROLOGY, 2025, 60 (02) : 235 - 246
  • [24] New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement
    Delaye, Matthieu
    Pernot, Simon
    BULLETIN DU CANCER, 2021, 108 (05) : 446 - 447
  • [25] FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
    Sridharan, Vishwajith
    Neyaz, Azfar
    Chogule, Abhijit
    Baiev, Islam
    Reyes, Stephanie
    Fritcher, Emily G. Barr
    Lennerz, Jochen K.
    Sukov, William
    Kipp, Benjamin
    Ting, David T.
    Deshpande, Vikram
    Goyal, Lipika
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5431 - 5439
  • [26] Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
    Hyung, Sujin
    Han, Boram
    Jung, Jaeyun
    Kim, Seung Tae
    Hong, Jung Yong
    Park, Se Hoon
    Zang, Dae Young
    Park, Joon Oh
    Park, Young Suk
    Kim, Kyoung-Mee
    Kang, Won Ki
    Lee, Jeeyun
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [27] A pilot study of ponatinib in cholangiocarcinoma patients with FGFR2 fusions.
    DeLeon, Thomas
    Alberts, Steven R.
    McWilliams, Robert R.
    Hubbard, Joleen Marie
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    Mody, Kabir
    Roberts, Lewis R.
    Salomao, Marcela
    Kipp, Benjamin
    Halfdanarson, Thorvardur Ragnar
    Murtaza, Muhammed
    Ramanathan, Ramesh K.
    Dueck, Amylou C.
    Borad, Mitesh J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [28] Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma
    Cleary, James M.
    Raghavan, Srivatsan
    Li, Yvonne Y.
    Spurr, Liam
    Wu, Qibiao
    Shi, Lei
    Brais, Lauren K.
    Odhiambo, Zunelly
    Goyal, Lipika
    Patel, Anuj K.
    Shinagare, Atul B.
    Clancy, Thomas E.
    Shapiro, Geoffrey
    Cerami, Ethan
    Sellers, William R.
    Hahn, William C.
    Cherniack, Andrew D.
    Bardeesy, Nabeel
    Meyerson, Matthew
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [29] FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma
    Mahipal, Amit
    Tella, Harsha
    Kommalapati, Anuhya
    Anaya, Daniel
    Kim, Richard
    CANCER TREATMENT REVIEWS, 2019, 78 : 1 - 7
  • [30] Real-world genomic testing, treatment, and outcomes in patients with cholangiocarcinoma with FGFR2 fusions/rearrangements.
    Borad, Mitesh J.
    Conner, Therese
    He, LiHong
    Kazerooni, Reza
    Salimi, Tehseen
    Epstein, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16168 - E16168
12345